CAMP4 Therapeutics Corporation CAMP 深 滬
等待開盤 05-23 09:30:00 美东时间
4.51
+0.110
+2.50%
華盛通- 最 高4.70
- 今 開4.48
- 成交量 7.62万股
- 最 低 4.40
- 昨 收 4.40
- 總市值 23.42万
- 52周最高 7.75
- 市盈率 靜 --
- 換手率 146.72%
- 52周最低 1.305
- 委 比 47.17%
- 總股本 5.19万
- 歷史最高 12.30
- 量 比 1.75
- 振 幅 6.82%
- 歷史最低 0.40
- 每 手 1
- 風險率 1.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy
The latest announcement is out from CAMP4 Therapeutics Corporation ( ($CAMP) )....
05-14 21:38
Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 48.39 percent increase over losses of $(0.62) per share
05-08 04:49
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
CAMP4 Therapeutics submitted its first clinical trial filing for CMP-002 in Australia, planning additional global filings in 2026 and initiating a Phase 1/2 trial in SYNGAP1 patients by late 2026. The company received Orphan Designation for CMP-002 from the EMA and entered a collaboration with CURE SYNGAP1 to support a natural history study. With $99 million in cash as of March 2026, CAMP4 expects its cash runway to extend into 2028.
05-07 20:05
CAMP4 Therapeutics Submits Reprint To bioRxiv Titled "Profiling and Targeting of Regulatory RNAs to Upregulate Gene Expression."
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human
04-28 20:07
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
Rodman & Renshaw Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $7
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $7.
04-14 23:03
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts changed outlook on top names. See complete view of rating changes, including upgrades/downgrades, on our analyst ratings page.
04-02 23:49
Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9
Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.
04-02 22:50
